Novel therapies for hemodialysis vascular access dysfunction: Fact or fiction!

Blood Purification

Volumn 23, Issue 1, 2005, Pages 29-35

  Roy Chaudhury, Prabir ^a,b   Kelly, Burnett S ^a   Melhem, Murad ^a   Zhang, Jianhua ^a   Li, Jinsong ^a   Desai, Pankaj ^a   Munda, Rino ^a   Heffelfinger, Sue C ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Arteriovenous fistulae; Drug eluting stents; Hemodialysis vascular access; Perivascular polymers; Polytetrafluoroethylene grafts; Radiation; Venous neointimal hyperplasia

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ARTICLE; BONE MARROW CELL; CELL TYPE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEMODIALYSIS; HEMODIALYSIS VASCULAR ACCESS DYSFUNCTION; HUMAN; INTIMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STENOSIS; THROMBOSIS; VASCULAR ACCESS; VASCULAR DISEASE;

ARTERIOVENOUS SHUNT, SURGICAL; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; POLYTETRAFLUOROETHYLENE; RENAL DIALYSIS;

EID: 11444270346     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082008     Document Type: Article

References (62)

1. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523-535.
2. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA: Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001;60:1164-1172.
3. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726-1736.
4. Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetra-fluoroethylene dialysis grafts. Kidney Int 2001;59:2325-2334.
5. DOQI. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis 2001;37(suppl 1):S137-S181.
6. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL: Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985;202:235-239.
7. Malovrh M: Native arteriovenous fistula: Preoperative evaluation. Am J Kidney Dis 2002;39:1218-1225.
8. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 2002;61:305-316.
9. Roy-Chaudhury P, Kelly BS, Narayana A, et al: Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Adv Ren Replace Ther 2002;9:74-84.
10. Roy-Chaudhury P, Kelly BS, Zhang J, et al: Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif 2003;21:99-110.
11. Keren G: Compensatory enlargement, remodeling, and restenosis. Adv Exp Med Biol 1997;430:187-196.
12. Libby P, Tanaka H: The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97-106.
13. Nakamura Y, Zhao H, Yutani C, Imakita M, Ishibashi-Ueda H: Morphometric and histologic assessment of remodeling associated with restenosis after percutaneous transluminal coronary angioplasty. Cardiology 1998;90:115-121.
14. Kwon HM, Sangiorgi G, Ritman EL, et al: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998;101:1551-1556.
15. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996; 94:1655-1664.
16. Shi Y, O'Brien JE, Jr., Mannion JD, et al: Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997;95:2684-2693.
17. Roy-Chaudhury P ML, Miller M, Reaves A, Armstrong J, Duncan H, Munda R, Kelly B, Heffelfinger S: Adventitial fibroblasts contribute to venous neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol 2001;12:301A.
18. Sata M, Saiura A, Kunisato A, et al: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-409.
19. Sata M, Hirata Y, Nagai R: Circulating recipient cells contribute to graft coronary arteriolosclerosis. J Cardiol 2002;39:48-49.
20. Yokote K, Take A, Nakaseko C, et al: Bone marrow-derived vascular cells in response to injury. J Atheroscler Thromb 2003;10:205-210.
21. Diao Y GM, Guthrie S, Scott E, Segal MS: Role of circulating progenitor cells in the development of venous intimal hyperplasia. J Am Soc Nephrol 2002;13:58A-59A.
22. Koc M, Bihorac A, Segal MS: Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients. Am J Kidney Dis 2003;42:704-712.
23. Griese DP, Ehsan A, Melo LG, et al: Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell-based vascular therapy. Circulation 2003;108:2710-2715.
24. Kong D, Melo LG, Mangi AA, et al: Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004;109:1769-1775.
25. Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB 3rd: Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995;91:1533-1539.
26. Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J: Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: Persistent benefi t at 6-month follow-up. J Am Coll Cardiol 1995;25:1451-1456.
27. Leon MB, Teirstein PS, Moses JW, et al: Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-256.
28. Raizner AE, Oesterle SN, Waksman R, et al: Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000;102:951-958.
29. Kelly BS, Narayana A, Heffelfinger SC, et al: External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous polytetrafluoroethylene (PTFE) graft stenosis. Int J Radiat Oncol Biol Phys 2002;54:263-269.
30. Roy-Chaudhury P, DZ, Duncan H, Foley J, Misra S: Endovascular radiation therapy reduces venous stenosis in PTFE dialysis access grafts. J Am Soc Nephrol 2004, in press.
31. Qian HS, Channon K, Neplioueva V, et al: Improved adenoviral vector for vascular gene therapy: Beneficial effects on vascular function and inflammation. Circ Res 2001;88:911-917.
32. von der Leyen HE, Gibbons GH, Morishita R, et al: Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
33. Shears LL 2nd, Kibbe MR, Murdock AD, et al: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
34. Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260-2268.
35. Tsui LV, Camrud A, Mondesire J, et al: p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ Res 2001;89:323-328.
36. Chang MW, Barr E, Seltzer J, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
37. Hayashi K, Nakamura S, Morishita R, et al: In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000;7:1664-1671.
38. Mann MJ, Conte MS: Transcription factor decoys for the prevention of vein bypass graft failure. Am J Cardiovasc Drugs 2003;3:79-85.
39. Mann MJ, Whittemore AD, Donaldson MC, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-1498.
40. Stone GW, Ellis SG, Cox DA, et al: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
41. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
42. Degertekin M, Serruys PW, Foley DP, et al: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-1613.
43. Brauner R, Laks H, Drinkwater DC Jr, et al: Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg 1997;114:53-63.
44. Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ: Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Controlled Release 1999;60:129-142.
45. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ: Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243-1249.
46. Chaux A, Ruan XM, Fishbein MC, et al: Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998;115:604-614.
47. Edelman ER, Nugent MA, Karnovsky MJ: Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition. Proc Natl Acad Sci USA 1993;90:1513-1517.
48. Kaul S, Cercek B, Rengstrom J, et al: Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: Role of nuclear factor-kappaB. J Am Coll Cardiol 2000;35:493-501.
49. Laham RJ, Sellke FW, Edelman ER, et al: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-1871.
50. Lopez JJ, Edelman ER, Stamler A, Morgan JP, Sellke FW, Simons M: Local perivascular administration of basic fibroblast growth factor: Drug delivery and toxicological evaluation [published erratum appears in Drug Metab Dispos 1996;24:1166]. Drug Metab Dispos 1996;24:922-924.
51. Golomb G, Fishbein I, Banai S, et al: Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996;125:171-182.
52. Kelly BMM, Desai P, Kasting G, Zhang J, Li J, Heffelfinger S, Rudich S, Roy-Chaudhury P: Perivascular paclitaxel polymers reduce neointimal hyperplasia and venous stenosis in PTFE arteriovenous grafts: A solution for hemodialysis vascular access ysfunction? J Am Soc Nephrol 2004, in press.
53. Dardik A, Liu A, Ballermann BJ: Chronic in vitro shear stress stimulates endothelial cell retention on prosthetic vascular grafts and reduces subsequent in vivo neointimal thickness. J Vasc Surg 1999;29:157-167.
54. Bowlin GL, Rittgers SE: Electrostatic endothelial cell transplantation within small-diameter (<6 mm) vascular prostheses: A prototype apparatus and procedure. Cell Transplant 1997;6:631-637.
55. Bowlin GL, Rittgers SE: Electrostatic endothelial cell seeding technique for small-diameter (<6 mm) vascular prostheses: Feasibility testing. Cell Transplant 1997;6:623-629.
56. Bowlin GL, Rittgers SE, Milsted A, Schmidt SP: In vitro evaluation of electrostatic endothelial cell transplantation onto 4 mm interior diameter expanded polytetrafluoroethylene grafts. J Vasc Surg 1998;27:504-511.
57. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S: Endothelial progenitor cells: New hope for a broken heart. Circulation 2003;107:3093-3100.
58. Shirota T, He H, Yasui H, Matsuda T: Human endothelial progenitor cell-seeded hybrid graft: Proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue Eng 2003;9:127-136.
59. Shi Q, Bhattacharya V, Hong-De Wu M, Sauvage LR: Utilizing granulocyte colony-stimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann Vasc Surg 2002;16:314-320.
60. Ohno T, Gordon D, San H, et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
61. Brieger D, Topol E: Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997;35:405-413.
62. Sousa JE, Costa MA, Abizaid A, et al: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.